Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT06464068 Recruiting - Clinical trials for Extrapulmonary Small Cell Carcinoma

AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA

DURVASCC
Start date: January 16, 2024
Phase: Phase 2
Study type: Interventional

This is a phase II, single-arm, multicenter study to evaluate the activity and safety of durvalumab in combination with carboplatin or cisplatin plus etoposide in patients with treated ES-EPSCC.

NCT ID: NCT06463834 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Start date: March 20, 2024
Phase: Phase 2
Study type: Interventional

This study is aimed to evaluate the efficacy and safety of sintilimab combined with chemotherapy (docetaxel+cisplatin+5-fluorouracil, DCF) in neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma.

NCT ID: NCT06463756 Recruiting - Laryngeal Carcinoma Clinical Trials

CT-based Radiomics and Deep Learning Models to Predict Thyroid Cartilage Invasion and Patient Prognosis in Laryngeal Carcinoma

Start date: August 13, 2023
Phase:
Study type: Observational

This retrospective study was to develop and verify a CT-based radiomics model, 2D deep learning model and 3D deep learning model to preoperatively predict the thyroid cartilage invasion of laryngeal cancer patients, so as to provide more accurate diagnosis and treatment basis for clinicians. And the performance of the aforementioned models was compared with two radiologists. In addition, the researchers investigated the prediction of survival outcomes of patients by the above optimal models.

NCT ID: NCT06463665 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25)

(VIRO-25)
Start date: July 2024
Phase: Phase 2
Study type: Interventional

This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor (ICI) vs. docetaxel for patients with advanced or metastatic NSCLC who have shown first disease progression (i.e., progressive disease not yet confirmed by further scan after initial scan showing progression) while on front-line treatment or maintenance ICI therapy after front-line treatment with platinum-doublet chemotherapy + ICI as standard of care.

NCT ID: NCT06463548 Not yet recruiting - Clinical trials for Biliary Tract Carcinoma

Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

To evaluate the efficacy and safety of irinotecan hydrochloride liposome injection combined with Capecitabine and Lenvatinib for second-line treatment in Patients With advanced or metastatic biliary tract carcinoma.

NCT ID: NCT06463522 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma

Start date: July 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1, open label clinical trial of tumor-infiltrating lymphocytes for the treatment of patients with hepatocellular carcinoma. The purpose of this study is to assess the safety of tumor-infiltrating lymphocytes therapy in patients with hepatocellular carcinoma.

NCT ID: NCT06463392 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Deep Learning-based sbORN Diagnostic Model

Start date: June 20, 2024
Phase:
Study type: Observational

Skull-base osteonecrosis (sbORN) is a severe long-term complication of nasopharyngeal carcinoma (NPC) post radiotherapy, which significantly diminish the quality of life, increase the risk of internal carotid artery rupture, and is frequently misdiagnosed as NPC recurrence. Novel diagnostic tools are therefore clinically significant. In this study, the investigators seek to ask if a deep-learning-based model shows a significantly higher sensitivity than radiologists. With a cross-sectional design, the investigators aim to recruit 312 participants in Sun Yat-sen Memorial Hospital, Guangzhou, China that meet the eligibility criteria.

NCT ID: NCT06462183 Not yet recruiting - Colorectal Cancer Clinical Trials

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

Start date: June 2024
Phase: Phase 1
Study type: Interventional

Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRCT

NCT ID: NCT06461624 Not yet recruiting - Clinical trials for Advanced Hepatocellular Carcinoma

Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma

Start date: July 1, 2024
Phase: Phase 1
Study type: Interventional

A phase I clinical study of 4th generation chimeric antigen receptor T Cells targeting glypican-3 ( CAR-GPC3 T Cells) in patients with advanced hepatocellular carcinoma.

NCT ID: NCT06456411 Recruiting - Breast Carcinoma Clinical Trials

Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer

Start date: July 12, 2022
Phase:
Study type: Observational

This clinical trial attempts to measure pain severity, location of pain, and feasibility in patients with cancer using functional near-infrared spectroscopy and virtual reality relaxation programs. Functional near-infrared spectroscopy and virtual reality relaxation programs may help relieve pain in patients with cancer who are receiving treatment.